吡格列酮对早期糖尿病肾病大鼠血清一氧化氮和一氧化氮合酶的影响.docVIP

· 904 · 医学研究生学报2011年9月第24卷第9期JMed Pastgra,Vol.24,No.9, September,2011 论 著 (基础研究) 吡格列酮对早期糖尿病肾病大鼠血清一氧化氮 和一氧化氮合酶的影响 杨前勇，聂 忠，宋宁燕 [摘要] 目的 糖尿病肾病(diabetic nephropathy,DN) 是糖尿病的慢性并发症和主要死因，其发病机制复杂，缺乏明确有 效治疗措施。文中探讨血清一氧化氮(nitric oxide,NO)、一氮化氮合酶(nitricoxide synthase,NOS)与 DN 的关系及吡格列酮 (Pioglitazone)对其影响。 方 法 采用链脲佐菌素诱导糖尿病模型，随机分为正常对照组、正常对照治疗组、糖尿病组、糖尿 病治疗组，2治疗组给予吡格列酮10mg/(kg ·d) 灌胃，每组10只。第10周末测定血糖、肾重/体重、24h 尿蛋白定量；检测各 组血清 NO 含量及总一氧化氮合酶(total nitric oxide synthases,T-NOS)、诱导型一氧化氮合酶(inducible nitric oxide synthases, iNOS)和结构型一氧化氮合酶(constructure nitric oxide synthases,cNOS)活性。 结果 糖尿病治疗组与糖尿病组比较，血糖 无显著差异(P0.05), 但肾重/体重和24h 尿蛋白定量明显降低(P0.01)。 糖尿病组 NO 水平和T-NOS、iNOS活性较正常 对照组明显增加(P0.05 或0.01),糖尿病治疗组 NO 水平和T-NOS、iNOS 活性较糖尿病组明显下降(P0.05 或0.01)。 cNOS 活性各组间比较无显著差异(P0.05)。 结论 早期 DN大鼠血清 NO含量和iNOS 活性明显升高。吡格列酮非降糖 的肾保护作用可能与其抑制 iNOS 活性和减少 NO 生成有关。 [关键词] 噻唑烷二酮；吡格列酮；糖尿病肾病； 一氧化氮； 一氧化氮合酶 [中图分类号] R582.2 [文献标志码] A [文章编号] 1008-8199(2011)09-0904-04 Pioglitazone reduces serum nitric oxide and nitricoxide synthase in rats with early diabetic nephropathy YANG Qian-yong, NIE Zhong, SONG Ning-yan (Depariment of Endocrinology,The 94th Hospital of the Chinese Peoples Liberation Army, Nanchang 330002, Jian- gxi,China) [Abstract] Objective Diabetic nephropathy(DN)is one of the common complications and a major cause of mortality in diabetes mellitus(DM). Its pathogenesis is so complicated that there are no definitely effective approaches to its management. This research was to investigate the changes of serum nitric oxide(NO)and nitricoxide synthase(NOS)in rats with early DN and their response to pioglitazone. Methods Forty male Wistar rats were randomly divided into four groups of equal number: normal control (NC), NC with pioglitazone(NCT),DM,and DM with pioglitazone(DMT). DM models were induced by streptozotocin. The rats in the NCT and DMT groups were treated intragastrically with pioglitazone at 10 mg/(kg ·d). The